New psychoactive substances consumption in opioid-use disorder patients
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Alías i Ferri, María
- dc.contributor.author Pellegrini, Manuela
- dc.contributor.author Marchei, Emilia
- dc.contributor.author Pacifici, Roberta
- dc.contributor.author Rotolo, Maria Concetta
- dc.contributor.author Pichini, Simona
- dc.contributor.author Pérez Mañá, Clara
- dc.contributor.author Papaseit Fontanet, Esther
- dc.contributor.author Muga, Roberto
- dc.contributor.author Fonseca Casals, Francina, 1972-
- dc.contributor.author Torrens, Marta
- dc.contributor.author Farré Albaladejo, Magí
- dc.date.accessioned 2022-07-04T06:21:42Z
- dc.date.available 2022-07-04T06:21:42Z
- dc.date.issued 2022
- dc.description.abstract (1) Background: Since the beginning of the 21st century, the large number and wide chemical variety of new psychoactive substances (NPS) that enter the market every year has become a public health problem. Given the rapidity with which the drug market is changing, many NPS are not clinically investigated and their effects and health risks are unknown. Drug testing is a very useful tool for this purpose, but, unfortunately, it is not very widespread in individuals with opioid-use disorder under detoxification treatment. The aim of this study is to investigate the use of illicit drugs and NPS in opioid-use disorder (OUD) patients on opioid agonist treatment. (2) Methods: A multicenter, descriptive, cross-sectional study was conducted at two addiction care services in Barcelona and Badalona, Spain. Urine samples were collected from OUD individuals attending these two centers, who anonymously donated a urine sample at the time of a periodical visit. Samples were analyzed by high-sensitivity gas chromatography-mass spectrometry (GC-MS) and ultra-high-performance liquid chromatography-high -resolution mass spectrometry (UHPLC-HRMS). (3) Results: Out of the 187 collected and analyzed urine samples, 27.3% were positive for any type of NPS and 8.6% were positive for new synthetic opioids, including fentanyl and its derivatives (NSO). Other frequently detected substances were benzodiazepines in 46.0% of samples, antipsychotics in 27.8% of samples, or cocaine and cannabis in 23.5% of samples. (4) Conclusion: A wide number of NPS, including NSO, have been detected in urine samples from an OUD population. A lack of NPS detection in standard drug screening among drug users can hide the identification of a potential public health problem.
- dc.format.mimetype application/pdf
- dc.identifier.citation Alías-Ferri M, Pellegrini M, Marchei E, Pacifici R, Rotolo MC, Pichini S, Pérez-Mañá C, Papaseit E, Muga R, Fonseca F, Torrens M, Farré M. New psychoactive substances consumption in opioid-use disorder patients. Biology (Basel). 2022 Apr 22;11(5):645. DOI: 10.3390/biology11050645
- dc.identifier.doi http://dx.doi.org/10.3390/biology11050645
- dc.identifier.issn 2079-7737
- dc.identifier.uri http://hdl.handle.net/10230/53663
- dc.language.iso eng
- dc.publisher MDPI
- dc.relation.ispartof Biology (Basel). 2022 Apr 22;11(5):645
- dc.rights © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri https://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword New psychoactive substances
- dc.subject.keyword Opioid-use disorder
- dc.subject.keyword Urine sample analysis
- dc.title New psychoactive substances consumption in opioid-use disorder patients
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion